WO2023198641 - MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONE
National phase entry:
Publication Number
WO/2023/198641
Publication Date
19.10.2023
International Application No.
PCT/EP2023/059304
International Filing Date
07.04.2023
Title **
[English]
MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONE
[French]
FORMULATIONS PHARMACEUTIQUES À LIBÉRATION MODIFIÉE COMPRENANT DE LA DÉFÉRIPRONE
Applicants **
CHIESI FARMACEUTICI S.P.A.
Via Palermo 26/A
43122 Parma, IT
Inventors
PERTILE, Marisa
c/o Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma, IT
GAZZANIGA, Andrea
c/o Università degli Studi di Milano
Via Festa del Perdono 7
20122 Milano, IT
CEREA, Matteo
c/o Università degli Studi di Milano
Via Festa del Perdono 7
20122 Milano, IT
CIRILLI, Micol
c/o Università degli Studi di Milano
Via Festa del Perdono 7
20122 Milano, IT
Priority Data
22167557.2
11.04.2022
EP
17/717,913
11.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1369 | |
| EPO | Filing, Examination | 7048 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 4310 |
Total: 13923 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the invention is also directed to delayed release tablets suitable either for twice daily administration or once daily administration. The invention is also directed to methods of making and using the same.[French]
L'invention concerne des compositions pharmaceutiques destinées à une administration orale comprenant de la défériprone. En particulier, l'invention concerne également des comprimés à libération retardée appropriés soit pour une administration deux fois par jour, soit une fois par jour. L'invention concerne également leurs procédés de fabrication et d'utilisation.